Latigo Biotherapeutics’ planned Nasdaq debut under ticker LTGO centers on a non-opioid pain pipeline anchored by late-stage Nav1.8 inhibitor LTG-001, positioned as a potential rival to Vertex’s Journavx. The August 2026 amended S-1 targets $16–$18 per share for 16 million shares, implying roughly $1.08 billion post-money valuation and $247–288 million in proceeds to fund Phase 3 advancement, FDA filing, and launch preparations. Recent private funding included a 2025 Series B at a $526 million valuation, while the broader 2026 biotech IPO rebound—driven by later-stage assets and improved sentiment—has lifted median raises above $280 million. Trader-implied odds cluster around the $1–1.15 billion range, reflecting the disclosed pricing midpoint amid execution risk and sector volatility.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$1.3B-$1.45B 25%
$1.15B-$1.3B 18%
$850M-$1B 8%
<$850M 5%
NEW
NEW
Aug 7, 2026
<$850M
5%
$850M-$1B
8%
$1B-$1.15B
42%
$1.15B-$1.3B
18%
$1.3B-$1.45B
25%
$1.45B+
30%
No IPO before October 2026
3%
$1.3B-$1.45B 25%
$1.15B-$1.3B 18%
$850M-$1B 8%
<$850M 5%
NEW
NEW
Aug 7, 2026
<$850M
$55 Vol.
5%
$850M-$1B
$170 Vol.
8%
$1B-$1.15B
$40 Vol.
42%
$1.15B-$1.3B
$20 Vol.
18%
$1.3B-$1.45B
$20 Vol.
25%
$1.45B+
$20 Vol.
30%
No IPO before October 2026
$20 Vol.
3%
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics’ planned Nasdaq debut under ticker LTGO centers on a non-opioid pain pipeline anchored by late-stage Nav1.8 inhibitor LTG-001, positioned as a potential rival to Vertex’s Journavx. The August 2026 amended S-1 targets $16–$18 per share for 16 million shares, implying roughly $1.08 billion post-money valuation and $247–288 million in proceeds to fund Phase 3 advancement, FDA filing, and launch preparations. Recent private funding included a 2025 Series B at a $526 million valuation, while the broader 2026 biotech IPO rebound—driven by later-stage assets and improved sentiment—has lifted median raises above $280 million. Trader-implied odds cluster around the $1–1.15 billion range, reflecting the disclosed pricing midpoint amid execution risk and sector volatility.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Market Opened: Aug 5, 2026, 5:52 AM ET
Volume
$345End Date
Aug 7, 2026Market Opened
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics’ planned Nasdaq debut under ticker LTGO centers on a non-opioid pain pipeline anchored by late-stage Nav1.8 inhibitor LTG-001, positioned as a potential rival to Vertex’s Journavx. The August 2026 amended S-1 targets $16–$18 per share for 16 million shares, implying roughly $1.08 billion post-money valuation and $247–288 million in proceeds to fund Phase 3 advancement, FDA filing, and launch preparations. Recent private funding included a 2025 Series B at a $526 million valuation, while the broader 2026 biotech IPO rebound—driven by later-stage assets and improved sentiment—has lifted median raises above $280 million. Trader-implied odds cluster around the $1–1.15 billion range, reflecting the disclosed pricing midpoint amid execution risk and sector volatility.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$345End Date
Aug 7, 2026Market Opened
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...Latigo Biotherapeutics’ planned Nasdaq debut under ticker LTGO centers on a non-opioid pain pipeline anchored by late-stage Nav1.8 inhibitor LTG-001, positioned as a potential rival to Vertex’s Journavx. The August 2026 amended S-1 targets $16–$18 per share for 16 million shares, implying roughly $1.08 billion post-money valuation and $247–288 million in proceeds to fund Phase 3 advancement, FDA filing, and launch preparations. Recent private funding included a 2025 Series B at a $526 million valuation, while the broader 2026 biotech IPO rebound—driven by later-stage assets and improved sentiment—has lifted median raises above $280 million. Trader-implied odds cluster around the $1–1.15 billion range, reflecting the disclosed pricing midpoint amid execution risk and sector volatility.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions